Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE
|
DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Alliance Disclosure of Insider Information pursuant to Section 17 (1) 1 of the Regulation (EU)
Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE Grünwald, September 10, 2020 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) and BioNTech SE, Mainz, Germany, have agreed that their production subsidiaries will cooperate on producing a COVID-19 vaccine. The production capacities at Dermapharm will be available to the cooperation partners BioNTech SE and Pfizer Inc. already when production of the vaccine begins. >End of the ad hoc announcement<
Contacts
10-Sep-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Dermapharm Holding SE |
| Lil-Dagover-Ring 7 | |
| 82031 Grünwald | |
| Germany | |
| Phone: | +49 (0)89 64 86-0 |
| E-mail: | ir@dermapharm.com |
| Internet: | ir.dermapharm.de |
| ISIN: | DE000A2GS5D8 |
| WKN: | A2GS5D |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1129961 |
| End of Announcement | DGAP News Service |
|
|
1129961 10-Sep-2020 CET/CEST
